BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 27376283)

  • 1. Discovery of a Potential HER2 Inhibitor from Natural Products for the Treatment of HER2-Positive Breast Cancer.
    Li J; Wang H; Li J; Bao J; Wu C
    Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27376283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative anti-proliferative effects of potential HER2 inhibitors on a panel of breast cancer cell lines.
    Zalloum H; AbuThiab T; Hameduh T; AlBayyari S; Zalloum W; Abu-Irmaileh B; Mubarak MS; Zihlif M
    Breast Cancer; 2020 Mar; 27(2):213-224. PubMed ID: 31559601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
    Tevaarwerk AJ; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Label-free LC-MS analysis of HER2+ breast cancer cell line response to HER2 inhibitor treatment.
    Di Luca A; Henry M; Meleady P; O'Connor R
    Daru; 2015 Aug; 23(1):40. PubMed ID: 26238995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of novel HER2 inhibitors against gastric cancer derived from flavonoid source of
    Babu TM; Rammohan A; Baki VB; Devi S; Gunasekar D; Rajendra W
    Drug Des Devel Ther; 2016; 10():3611-3632. PubMed ID: 27853354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches.
    Rampogu S; Son M; Baek A; Park C; Rana RM; Zeb A; Parameswaran S; Lee KW
    Comput Biol Chem; 2018 Jun; 74():327-338. PubMed ID: 29702367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3D pharmacophore-based virtual screening, docking and density functional theory approach towards the discovery of novel human epidermal growth factor receptor-2 (HER2) inhibitors.
    Gogoi D; Baruah VJ; Chaliha AK; Kakoti BB; Sarma D; Buragohain AK
    J Theor Biol; 2016 Dec; 411():68-80. PubMed ID: 27693363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
    Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel EGFR/HER2 dual inhibitors bearing a oxazolo[4,5-g]quinazolin-2(1H)-one scaffold.
    Yin S; Tang C; Wang B; Zhang Y; Zhou L; Xue L; Zhang C
    Eur J Med Chem; 2016 Sep; 120():26-36. PubMed ID: 27187856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
    Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G
    Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapy.
    Zhao H; Faltermeier CM; Mendelsohn L; Porter PL; Clurman BE; Roberts JM
    Oncotarget; 2014 Dec; 5(24):12704-14. PubMed ID: 25587029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
    Zavodovskaya M; Campbell MJ; Maddux BA; Shiry L; Allan G; Hodges L; Kushner P; Kerner JA; Youngren JF; Goldfine ID
    J Cell Biochem; 2008 Feb; 103(2):624-35. PubMed ID: 17562544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR, HER2 target based molecular docking analysis, in vitro screening of 2, 4, 5-trisubstituted imidazole derivatives as potential anti-oxidant and cytotoxic agents.
    Guda R; Kumar G; Korra R; Balaji S; Dayakar G; Palabindela R; Myadaraveni P; Yellu NR; Kasula M
    J Photochem Photobiol B; 2017 Nov; 176():69-80. PubMed ID: 28964888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
    Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitor Response to HER2 G776(YVMA) In-frame Insertion in HER2-positive Breast Cancer.
    Zheng YB; Yu Y; Chen B; Hu JL; Jing T; Zhang XP
    Cancer Invest; 2016; 34(3):123-9. PubMed ID: 26934461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporation of lapatinib into human serum albumin nanoparticles with enhanced anti-tumor effects in HER2-positive breast cancer.
    Wan X; Zheng X; Pang X; Zhang Z; Zhang Q
    Colloids Surf B Biointerfaces; 2015 Dec; 136():817-27. PubMed ID: 26539808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.